Lonnie Moulder is the founding general partner of Tellus BioVentures and a venture advisor to New Enterprise Associates. He most recently served as CEO and director of TESARO since cofounding the company in 2010. Acquired by GlaxoSmithKline in January 2019, TESARO is a Boston-based oncology-focused biopharmaceutical company. He previously served as president and CEO of Abraxis BioScience, Inc., acquired by Celgene Corporation in 2010. In 2008, Lonnie served as vice chairman and executive vice president of Eisai Corporation of North America following Eisai’s acquisition of MGI PHARMA, where he served as president and CEO beginning in 2003. Numerous cancer patients have benefitted from products developed and launched by Lonnie’s teams. He raised over $2 billion of public and private capital and led organizations that were acquired for a combined value of over $10 billion. Lonnie is a Temple University trustee, chair of the Temple University Japan (TESS) board, and serves on the Fox Chase Cancer Center board. He is a council member for Chicago Booth and the Polsky Center for Entrepreneurship and Innovation. Lonnie is member of the board of the Moulder Family Charitable Foundation and chair of the board of directors of Trevena, Inc. He is also the owner-operator of the Commodore Farm & Vineyard. Lonnie was co-recipient of E&Y “Entrepreneur of the Year” 2017 National Overall, National Life Sciences and New England Life Sciences award and named Institutional Investor’s “2018 Best Biotechnology Mid-Cap CEO”. Lonnie received a pharmacy degree from Temple University, and an MBA from Chicago Booth.